Lidocaine Overdoses Surge, Driving Local Anesthetic Deaths

New research ⁢reveals a significant increase in ⁣lidocaine-related fatalities, with nearly all cases involving doses far exceeding recommended limits.

Local anesthetics, vital⁣ for pain management during medical procedures, are increasingly linked to severe toxicity, with lidocaine emerging as a primary concern. A recent study published in BMJ Regional Anesthesia & Pain Medicine highlights a concerning trend: while⁤ deaths from non-lidocaine local anesthetics ⁣have decreased, lidocaine-related fatalities have‍ surged, notably in⁣ recent years.

“Thes⁢ findings highlight the need for enhanced administrative guidance on lidocaine use, greater awareness of the risks ⁢of high ⁢doses of lidocaine, and improved strategies for preventing and managing severe lidocaine-induced toxicity,” stated lead author Michael Fettiplace, MD, assistant professor in the Department of Anesthesiology at the University of Illinois Chicago College of Medicine.

Digging Through Poison Records ⁢for Answers

Local anesthetics are ⁤indispensable tools for numbing pain, commonly used in minor surgical procedures. However, improper governance ‍can lead to systemic toxicity.In⁣ response to this risk, the American Society of Regional Anesthesia and Pain Medicine ⁢issued a practice advisory in 2010 to guide the prevention ⁢and management of systemic toxicity from ⁤local anesthetics.

Researchers hypothesized that these guidelines would lead⁣ to a reduction in related poisonings and ⁢deaths. To test this, they analyzed data from the American Association of poison Control Centers’ National Poison ⁣Data System,‍ spanning ⁢from 1983 to⁢ 2022.

The study employed a case-non-case disproportionality analysis starting in 2001, the year lidocaine was first distinctly categorized in the database. By comparing poisoning and ⁢death reports from before and after the 2010 ‍guideline release, the researchers calculated the reporting odds ratio for the relative frequency of lidocaine-related deaths and poisonings. Trends in poisoning‍ and death ⁣rates were ⁢further validated using multiple linear regression‍ and ⁣Poisson regression, respectively.

Nearly All Lidocaine Deaths Involved High Dosage

The data revealed a stark contrast ⁢in mortality rates.⁤ From 2001 to 2022, 0.11% of lidocaine⁢ poisoning reports resulted in death,‍ compared to ⁣a significantly lower 0.012% for non-lidocaine poisoning reports.

According to a news release accompanying the study, “The relative risk of death from a local anesthetic more than doubled between 2011 and ⁣2022 compared with ⁣the preceding decade, driven by an⁤ increase⁢ in reports ‍of death associated with lidocaine.”

Further investigation ⁢into 59 individual death cases involving local ⁢anesthesia poisoning between⁢ 1985 and 2022 (comprising 24 women with a median age of 47.5 years) found that lidocaine was implicated in ⁢82% of fatalities occurring between 2011 and 2022.

A particularly alarming finding was that nearly all lidocaine-related deaths involved doses exceeding the recommended maximum. One reported case involved a staggering dose of 48,000 mg.

“Given that the lidocaine package insert states that ‘in ‍general it is recommended that the maximum total dose should not exceed 500 mg,’ the ease of access⁤ to such large doses of lidocaine is alarming,” the investigators noted.

The study acknowledges limitations, including the ⁢potential for underreporting in both clinical and National Poison Data ⁢system data. The findings underscore the urgent need for clearer ⁣dosing guidelines for lidocaine and improved strategies for managing severe lidocaine‍ toxicity.

The authors reported no specific funding for this research. Guy Weinberg is an officer and shareholder of ResQ Pharma, Inc.